Health and Medical Devices News
Curis Announces Dosing of First Patient in CUDC-101 Phase Ib Expansion Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers. CUDC-101 is a first-in-class small molecule drug candidate that has been designed as an inhibitor of histone deacetylase (HDAC), epidermal
…
One Call Medical’s Proprietary Analytics Reveal Typical Payer Experiences Two-Thirds “Unmanaged” Diagnostic Radiology Referrals in Workers’ Compensation
PARSIPPANY, N.J.--(BUSINESS WIRE)--One Call Medical’s Proprietary Analytics Reveal Typical Payer Experiences Two-Thirds “Unmanaged” Diagnostic Radiology Referrals in Workers’ Compensation
…
Sirona Reports Fiscal 2010 Third Quarter Results
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the three and nine months ended June 30, 2010. Third Quarter Fiscal 2010 vs. Third Quarter Fiscal 2009 Financial Results Revenue was $182.4 million, an increase of $1.8 million or up 1.0% (up 6.0% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 17.7% (up 22.0% constant currency); CAD CAM
…
AngioDynamics to Participate in the 30th Annual Canaccord Genuity Growth Conference
ALBANY, N.Y.--(BUSINESS WIRE)--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will present at the 30th Annual Canaccord Genuity Growth Conference in Boston on Thursday, August 12, 2010, at 1 p.m. Eastern Time. Jan Keltjens, President and CEO, will review the Company’s business strategy and historical financial results. Attendance at the conference is by invitatio
…
Comitê Diretor Independente da Alcon comenta oposição do RiskMetrics Group e da Glass Lewis à escolha dos indicados pela Novartis para o Corpo de Diretores da Alcon
HUENENBERG, Suíça--(BUSINESS WIRE)--O Comitê Diretor Independente da Alcon (“IDC”) anunciou hoje que o RiskMetrics Group, Inc. e a Glass Lewis & Co., dois líderes globais em gerenciamento de risco, governança corporativa e representação de acionistas, recomendaram que os acionistas minoritários da Alcon votassem contra todos os cinco indicados da Novartis AG’s (“Novartis”) para o conselho diretor da Alcon. Como previamente anunciado, e segundo os termos dos acordos entre a Novartis e a Nestl
…
アルコンの独立取締役委員会がアルコン取締役会に対するノバルティス被指名人の選挙にリスクメトリックス・グループとグラス・ルイスが反対だと指摘
スイス・ヒューネンベルク--(BUSINESS WIRE)--（ビジネスワイヤ） -- アルコンの独立取締役委員会（IDC）は本日、リスク管理とコーポレートガバナンス、議決権行使助言の世界的リーダーであるリスクメトリックス・グループとグラス・ルイス・アンド・カンパニーの2社が、アルコン取締役会に対するノバルティスＡＧ（ノバルティス）の被指名人5人すべてにアルコンの少数株主が反対票を投ずることを推奨したと発表しました。先に発表したように、ノバルティスとネスレSAが2008年に締結した契約の条項に基づいて、アルコンの株主は2010年8月16日に開催される臨時総会でノバルティスが指名した取締役に対する条件付き選挙で投票することになります。 リスクメトリックスは8月1日付で顧客に送った強い言い回しの報告で、合併提案と少数株主に関する立場の点でノバルティスを非難しました。リスクメトリックスは、来る選挙の結果に疑問の余地がないものの、来る選挙における少数株主の投票はノバルティスによる支配権獲得の試みに対する「国民投票」とみなされる見通しであると記しています。リスクメトリックスは、「小数株主の投票に
…
New Market Reports on Drugs & Biotechnology Added by MarketPublishers.com
LONDON--(BUSINESS WIRE)--Market Publishers Ltd announces that new market research reports on Drugs & Biotechnology are available in its catalogue.
…
El Comité Directivo Independiente de Alcon advierte oposición de parte de RiskMetrics Group y Glass Lewis con respecto a la elección de los representantes de Novartis para integrar la Junta Directiva de Alcon
HUENENBERG, Suiza--(BUSINESS WIRE)--El Comité Directivo independiente de Alcon (Independent Director Committee, IDC) anunció hoy que RiskMetrics Group, Inc. y Glass Lewis & Co., dos líderes mundiales en gestión de riesgo, gobierno corporativo y servicios de consultoría de representación, han recomendado que los accionistas minoritarios de Alcon voten en contra de los cinco representantes de Novartis AG (“Novartis”) designados para integrar la Junta Directiva de Alcon. Según se anunció anteri
…
NeuroMetrix, Inc. Announces Date for 2010 Second Quarter Financial Results Conference Call
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2010 second quarter financial results before the opening of the market on Tuesday, August 10, 2010. The Company will host a conference call and webcast at 8:00 A.M. Eastern time on August 10, 2010 to discuss its second quarter financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 866-314-5232 and using the confi
…
Le Comité de direction indépendant d’Alcon prend acte de l’opposition du RiskMetrics Group et de Glass Lewis à l’élection des membres désignés par Novartis pour le Conseil de direction d’Alcon
HUENENBERG, Suisse--(BUSINESS WIRE)--Le Comité de direction indépendant d’Alcon (« IDC ») a annoncé aujourd’hui que RiskMetrics Group, Inc. et Glass Lewis & Co, deux leaders internationaux en gestion du risque et en gouvernance d’entreprise et services de conseil par procuration, ont tous deux recommandé que les actionnaires minoritaires d’Alcon votent contre les cinq membres désignés par Novartis (« Novartis ») pour le Conseil de direction d’Alcon. Ainsi qu’annoncé antérieurement, en vertu
…
NeuroMetrix to Present at Canaccord Genuity 30th Annual Growth Conference
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a health care company transforming patient care through neurotechnology, today announced that Shai Gozani, CEO, will be presenting at the Canaccord Genuity 30th Annual Growth Conference at the InterContinental Hotel, Boston, MA on August 10, 2010 NeuroMetrix's presentation is scheduled for Tuesday, August 10, 2010 at 3:30 pm (EDT). A live audio webcast will be available on the investor relations section of our corporate website -
…
Doctors in New South Wales and Victoria Become First in Australia to Treat Patients With Aortic Aneurysms Using GORE® DrySeal Sheath
SYDNEY & FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W.L. Gore & Associates (Gore) announced today the first clinical cases in Australia involving the revolutionary GORE® DrySeal Sheath. The sheath aids in minimally invasive treatment of patients with abdominal aortic aneurysms (AAA) utilizing the GORE® EXCLUDER® AAA Endoprosthesis and thoracic aortic aneurysms (TAA) utilizing the GORE® TAG® Thoracic Endoprosthesis. The first successful procedures were performed by Thomas Daly, MD, at Westmead Hospit
…
LecTec Corporation Announces Four Directors Not Standing For Re-election
TEXARKANA, Texas--(BUSINESS WIRE)--LecTec Corporation (OTCBB: LECT) announced today that Judd Berlin, Andy Rollwagen, Dr. Daniel Sigg and Ramanathan Periakaruppan will not be standing for reelection to the Board of Directors at the September 22, 2010, Annual Shareholders Meeting. The Proxy Statement for the Annual Meeting, which will include information concerning the slate of directors to be recommended by the Board, is expected to be mailed around August 20, 2010. Greg Freitag, LecTec CEO, com
…
SRI/Surgical Express, Inc. Second Quarter 2010 Conference Call
TAMPA, Fla.--(BUSINESS WIRE)--SRI/Surgical Express, Inc. (SRI Surgical) (NASDAQ:STRC), a leading provider of reusable surgical device reprocessing services supporting the healthcare industry, will hold its quarterly conference call to discuss second quarter results on Monday, August 9, 2010, at 5:00 p.m. Eastern Time (4 p.m. Central Time). This call is being webcast by Thomson Reuters and can be accessed at SRI’s Web site at www.srisurgical.com. Participants can use the following call-in informa
…
Orthovita Reports 2010 Second Quarter Financial Results And Updates Full Year Financial Guidance
MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, reported financial results for the quarter ended June 30, 2010. Product sales for the second quarter of 2010 were $23.9 million compared to $24.5 million for the second quarter of 2009. Product sales for the second quarter of 2009 included $0.6 million from the sale of Vitomatrix™, a bone graft material used in dental products. There were no Vitomatrix sales in the second quarter of 2010 and
…
Teleflex Announces Refinancing Transactions
LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) today announced its intention to implement the following refinancing transactions: an underwritten public offering, subject to market and other conditions, of $350 million aggregate principal amount of Teleflex’s convertible senior subordinated notes due 2017 (or up to $400 million if the 13-day option to purchase additional notes Teleflex expects to grant the underwriters is exercised in full); amend certain terms of
…
DaVita 2nd Quarter 2010 Results
DENVER--(BUSINESS WIRE)--DaVita Inc. (NYSE: DVA) today announced results for the quarter ended June 30, 2010. Net income attributable to DaVita Inc. for the three and six months ended June 30, 2010 excluding after-tax debt redemption charges of $2.5 million, or $0.02 per share, was $110.4 million and $219.8 million, or $1.06 and $2.10 per share, respectively. This compares to net income attributable to DaVita Inc. for the three and six months ended June 30, 2009 of $105.8 million and $202.0 mill
…
Wright Medical Group, Inc. Reports Results for Second Quarter Ended June 30, 2010
ARLINGTON, Tenn.--(BUSINESS WIRE)--Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market, today reported financial results for its second quarter ended June 30, 2010. Net sales totaled $127.7 million during the second quarter ended June 30, 2010, representing a 7% increase over net sales of $118.9 million during the second quarter of 2009. Foreign currency did not have a significant impact
…
Zeta Instruments Provides Key Solutions for Biotech and Microfluidics Applications
PORTLAND, Ore.--(BUSINESS WIRE)--Zeta provides key measurement solutions for Biotech and Microfluidics apps. DNA-sequencing innovator, IntegenX, selects Zeta-20™ optical metrology system for 3D measurement of micro-channel biochips.
…
Covidien公布2010财年第三季度业绩
都柏林--(BUSINESS WIRE)----(美国商业资讯)--Covidien plc（纽交所交易代码：COV）今日公布了公司2010财年第三季度（2010年4月-6月）的业绩报告。公司第三季度净销售额达25.6亿美元，较去年25.2亿美元的水平高2%，且季度销售额的增长并未受到汇率变动的影响。 2010年第三季度的毛利润率为55.6%，比去年同期的54.4%水平高1.2个百分点。更好的业绩反映了医疗器械部门产品组合的优势、改制计划所带来的效益以及有利的汇率变化。 2010年第三季度的营业和管理费用比上年同一季度略增。第三季度的研发费用占净销售额4.3%，而上年同期的销售额占比为5.2%。2009年第三季度所发生的研发费用包括公司制药部门两笔交易所发生的3000万美元特许费。 在2010年第三季度，公司公布的营业利润为5.39亿美元，高于去年同期的4.41亿美元。2010年第三季度经调整的经营性利润在剔除所附非美国会计准则季度对账表中的特殊科目后为5.69亿美元，高于去年同期的5.35亿美元。2010年第三季度经调整的经营性利润在剔除特殊科目后占销售额的22.2%，高于去年的21
…
